appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Strides Pharma Science Ltd
STAR
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
High Pledged Promoter HoldingLower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Increased Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has increased by 2.71%
Recent NewsAll news
Strides Pharma To Spin Off Contract Manufacturing Unit Into Stelis Biopharma
9 hours ago•Bloomberg Quint
Strides Pharma to spin off contract development unit, announces swap ratio of 1:2
11 hours ago•Business Today
Strides Pharma Jumps Over 8% After U.S. FDA Approves Drug To Reduce Heart Issues
16 hours ago•Bloomberg Quint
Recent EventsAll events
Press Release
Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 23, 2023, titled "Strides receives USFDA approval for Icosapent Ethyl Capsules". | Download
Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 23, 2023, titled "Strides receives USFDA approval for Icosapent Ethyl Capsules". | Download
Board Meeting Intimation
Cash Dividend
Final • Div/Share: ₹ 1.5
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 2.82%